行 业 及 产 业 美容护理 2025 年 07 月 13 日 行 业 研 究 / 行 业 点 评 相关研究 证 券 研 究 报 告 证券分析师 王立平 A0230511040052 wanglp@swsresearch.com 王盼 A0230523120001 wangpan@swsresearch.com 聂霜 A0230524120002 nieshuang@swsresearch.com 联系人 王立平 (8621)23297818× wanglp@swsresearch.com ⚫ 本周化妆品医美板块表现弱于市场。2025 年 7 月 4 日至 2025 年 7 月 11 日期间，申 万美容护理指数上涨 1.5%，表现弱于市场。其中，申万化妆品指数上涨 2.6%，强于申 万 A 指 1.1pct；申万个护用品指数基本持平，弱于申万 A 指数 1.6pct。 请务必仔细阅读正文之后的各项信息披露与声明 本研究报告仅通过邮件提供给 中庚基金 使用。1 再生药械再添两员，轻医美概念方兴未艾 看好 ——化妆品医美行业周报 20250713 - 本期投资提示： ⚫ 周观点：再生药械再添两员，轻医美概念方兴未 ...

石油进口依存度高达73%，能源安全如何保障？抗生素、农药、塑料进入食物链，还有安全的食品吗？全球抑郁 症和焦虑症急剧上升，解决方案在哪里？……"这些看似不相关的问题，其实都可以用合成生物的知识来解决。"7 月11日，新京报小记者们走进华熙生物合成生物科学馆，跟随着讲解员的解说，共同推开"细胞工厂"的科学大 门。 7月11日，新京报小记者们走进华熙生物合成生物科学馆。新京报记者徐彦琳 摄 探秘"细胞工厂" "葡萄放的时间长了就变成了葡萄酒，猪肉发酵后就成了火腿——这些都是自然发酵的产物，也就是第一代生物科 技。"进入合成生物科学馆，小记者们在讲解员的带领下了解生物科技。讲解员告诉小记者，第二代生物技术是定 向发酵，即找到特定功能的微生物，将自然资源定向转化为人们需要的产品；第三代生物技术是合成生物技术， 通过设计改造微生物定向发酵，让"细胞工厂"产出人类所需要的各种东西。 "随着人口爆炸和三次工业革命，人们的生活发生天翻地覆变化的同时，地球也面临了资源能源短缺、环境污染、 自然灾害频发、重大传染性疾病等危机。如何让自然资源可持续地为人类服务呢？答案或许就在合成生物技 术。"讲解员说道。 讲解员带领小记者们来到一 ...

Group 1 - The core viewpoint indicates that Huaxi Biological (688363) has a strong overall score of 50.30, suggesting a robust performance in the market [1] - The main cost analysis shows that the current main cost is 51.41 yuan, with a 5-day average cost of 51.21 yuan and a 20-day average cost of 50.69 yuan, indicating a stable pricing trend [1] - The stock has not experienced any limit-up or limit-down events in the past year, reflecting a stable trading environment [1] Group 2 - The technical analysis identifies a short-term resistance level at 51.52 yuan and a support level at 50.35 yuan, indicating potential price fluctuations within this range [2] - The funding flow data for July 11, 2025, shows a net outflow of 723.83 million yuan from main funds, which is 5% of the total transaction volume, suggesting cautious market sentiment [2] - The related industry sectors, including beauty care, medical devices, cosmetics, and medical beauty, show minor percentage changes, indicating a relatively stable market environment [2]

Core Viewpoint - Huaxi Biological has reported a seemingly contradictory financial performance for 2024, with total revenue of 5.371 billion yuan, a year-on-year decline of 11.61%, and a net profit of 174 million yuan, down 70.59%. However, the company increased its R&D investment by 4.46% to a record high of 466 million yuan, representing 8.68% of its revenue, positioning it among the leaders in A-shares [2][10]. Financial Performance - Total revenue for Huaxi Biological in 2024 was 5.371 billion yuan, a decrease of 11.61% year-on-year [2]. - Net profit fell to 174 million yuan, a significant drop of 70.59% [2]. - R&D investment reached 466 million yuan, marking a 4.46% increase and a historical high [2]. - The R&D expense ratio was 8.68%, placing the company at the forefront of the A-share market [2][10]. Business Strategy - The company aims to return to an entrepreneurial organization to awaken its innovative capabilities, as stated by Chairman Zhao Yan [2]. - Huaxi Biological's international revenue from raw materials reached 608 million yuan, a year-on-year increase of 17.65%, supported by FDA certification [5]. - The medical terminal business generated 1.44 billion yuan, a remarkable increase of 32.03%, becoming the largest revenue contributor [6]. - The functional skincare segment saw revenue decline by 31.62% to 2.569 billion yuan due to intensified market competition and channel adjustments [6]. R&D and Innovation - Huaxi Biological has established eight R&D platforms and holds 580 valid patents, with 392 applicable to its main business [7]. - The company is transitioning from a focus on hyaluronic acid to two foundational sciences: glycoscience and cell biology [9]. - The R&D team consists of 920 members, reflecting the company's commitment to long-term investment in innovation [10]. Market Position and Future Outlook - The FDA certification is expected to facilitate Huaxi Biological's expansion into high-end markets in Europe and the United States [4]. - The company is diversifying its business across four major fields: raw materials, medical devices, functional foods, and tissue engineering, creating a "cell-level anti-aging" ecosystem [9]. - Despite short-term profit pressures, Huaxi Biological announced a cash dividend of 52.62 million yuan, accounting for 30.19% of its net profit [9].

Industry Overview - The medical beauty injection materials industry in China has a limited number of publicly listed companies, primarily including Huaxi Biological, Haohai Biological, Aimeike, and Juzhi Biological, with most companies involved in the supply of upstream raw materials [1][7]. Company Summaries - Huaxi Biological is a global leader in hyaluronic acid, with a projected revenue of 53.71 billion yuan in 2024, and has expanded into collagen products through acquisitions [2][9]. - Haohai Biological has secured exclusive rights for domestic and international botulinum toxin products and is focusing on a dual product line of hyaluronic acid and botulinum toxin [6][15]. - Aimeike is expected to generate approximately 29.60 billion yuan in sales for its medical beauty injection materials in 2024, emphasizing high-end products [9][15]. - Juzhi Biological is projected to achieve sales of around 55.20 billion yuan in 2024, focusing on collagen products and leading the industry in standard-setting [9][15]. Sales and Production Data - Huaxi Biological has sold over 10 million units of its products, while Haohai Biological and Aimeike have sales around 7 million units each [13]. - Juzhi Biological's collagen products have a sales volume of approximately 55.20 billion yuan, indicating a strong market presence [11][13]. Business Strategies - Huaxi Biological is focusing on core technologies in glyco-biology and cell biology, aiming to enhance its position in the extracellular matrix and anti-aging sectors [15]. - Haohai Biological is pursuing international collaborations and technology imports to strengthen its product offerings and market competitiveness [15]. - Aimeike is developing a high-end product matrix centered on regenerative materials, with significant investments in training and technology [15]. - Juzhi Biological is leading the development of industry standards and expanding its product offerings in the collagen segment [15]. Regional Distribution - The majority of medical beauty injection material companies are concentrated in Shandong Province, with key players in raw material production and equipment manufacturing [7].

Core Viewpoint - Huaxi Biological Technology Co., Ltd. has received a "zero defect" result from the FDA, indicating the highest level of compliance in its quality management system, which will enhance its global market competitiveness and facilitate overseas business expansion [1][2]. Group 1: FDA Audit and Certification - The FDA audit lasted five days and was conducted according to ICH Q7 guidelines, covering six major systems including quality systems and laboratory systems, confirming the company's meticulous management and commitment to quality [2]. - This is not the first time Huaxi Biological has received a "zero defect" recognition; it previously passed a similar audit by the Korean MFDS in February 2025 [2]. - The company has successfully passed five FDA audits, one PMDA audit in Japan, and two MFDS audits in Korea for its sodium hyaluronate raw materials [2]. Group 2: Global Market Position - Huaxi Biological has established a significant presence in the global market, holding 34 registration qualifications across various countries, including the EU, the US, Japan, and Korea, making it one of the suppliers with the most comprehensive registrations for pharmaceutical-grade sodium hyaluronate [2][4]. - The company has a marketing and supply chain network spanning over 70 countries and regions, with overseas subsidiaries in key markets such as the US, France, Japan, and South Korea [4]. Group 3: Product Development and Recognition - In addition to raw materials, Huaxi Biological has received global recognition in skin science innovation and medical devices, recently obtaining a medical device registration certificate from Brazil's ANVISA, known for its stringent regulatory standards [4]. - The company has accumulated over 70 medical device and skincare product registrations across more than 15 countries or regions [4]. Group 4: Long-term Strategy and Investment - Huaxi Biological emphasizes long-term research and development investment, maintaining high standards and a stable supply chain to build a strong foundation for quality products and brand development [5]. - The company follows a "technology breakthrough—quality control—global compliance—standard leadership" model, focusing on international standards and resource allocation to enhance its industrial capabilities and product standards [5].

当业内每个上游企业都能拿出一个独家技术时，到底是喜是忧？ 在上周的一次化妆品行业展会上，剁椒Spicy直观地见证了护肤行业上游端的技术内卷。走过紧紧挨着的几十家供应商展台，几乎每个企业都能拿出一个 号称独家的成分，以及完备的证书。 丝素蛋白肽、重组三螺旋胶原蛋白、重组贻贝粘蛋白......五花八门的成分带领着一堆形态各异的产品，招呼着路过的每一位潜在客户。为了更清晰地展示 技术，除了具体的试用产品，就连活性蛋白开发过程中的不同形态，也都分装展示。 几乎每走两步，就会被成分商"拦截"安利一种新成分，甚至还没有开口问，对方就能一眼看出你的担忧，并承诺可以从产品到证书全链路代理。 这与当前护肤市场的C端趋势完全一致，自从部分品牌搭载技术成为大爆品之后，每个品牌，甚至每个产品的包装上，都加上了多个专业名词，从成分、 技术，甚至添加浓度上，试图找到稀缺的市场占位，复制商业神话。 技术的内卷对消费者是一件好事，毕竟积极竞争、主动投入的结果是实现量产，最终会诞生高性价比产品。但这种美好，被华熙生物和巨子生物的一场技 术话语权争夺战打破了。 人们发现，一种被大张旗鼓宣传的成分，如何检测，是否添加，能否透皮，全都无法获得最基本 ...

Group 1 - The establishment of Huaxi Tang'an Bio-Tech in Guangming marks a significant strategic deployment for Huaxi Bio, expanding its diversification beyond hyaluronic acid and establishing a global non-animal heparin full industry chain platform in the Guangdong-Hong Kong-Macao Greater Bay Area [2] - Huaxi Bio focuses on synthetic biology, with four main business segments: bioactive raw materials, pharmaceuticals and medical devices, skin science innovation, and nutritional science innovation, featuring brands such as Runzhi, Runbaiyan, Kuadi, Mibeier, and BM Jihuo [2] - Huaxi Tang'an has achieved multi-dimensional technological breakthroughs in the field of fully enzymatic synthesis of heparin, with applications in cosmetics, pharmaceuticals, and medical devices, serving as key drugs for the prevention and treatment of thromboembolic diseases, myocardial infarction, and anticoagulation in cardiovascular surgeries [2] Group 2 - The signing ceremony included agreements with Guangming District, the National Bio-Manufacturing Industry Innovation Center, and Xingbo Shenghui Private Venture Capital Fund for landing and angel round financing [3] - A roundtable forum titled "Synthetic Biology Empowering Heparin Industry Transformation" was held with key figures from academia and industry, including Zhang Xian'en, Guo Xueping, Ma Yingfei, Gu Zheyi, and Fang Xing [3] Group 3 - Guangming District has gathered over 130 enterprises in the synthetic biology field, with an estimated industry valuation of nearly 40 billion [4]

晨光生物：上半年净利润预增102.33%–132.38% 7月9日晚，晨光生物（300138）发布2025年半年度业绩预告，公司预计2025年上半年实现归属于上市公 司股东的净利润2.02亿元至2.32亿元，同比增长102.33%至132.38%。 资料显示，晨光生物成立于2000年4月，主营业务是天然植物提取物。 所属行业：农林牧渔–农产品加工–其他农产品加工 北方稀土：上半年净利润预增1882.54%–2014.71% 7月9日晚，北方稀土（600111）发布2025年半年度业绩预告，公司预计2025年上半年实现归属于母公司 所有者的净利润9亿元至9.6亿元，同比增长1882.54%至2014.71%。 资料显示，北方稀土成立于1997年9月，主营业务是生产经营稀土原料产品、稀土功能材料产品及部分 稀土终端应用产品。 所属行业：有色金属–小金属–稀土 友发集团：上半年净利润预增151.69%–178.93% 7月9日晚，友发集团（601686）发布2025年半年度业绩预告，公司预计2025年上半年实现归属于公司股 东的净利润2.77亿元至3.07亿元，同比增长151.69%至178.93%。 资料显示，友 ...

证券代码：688363 证券简称：华熙生物 公告编号：2025-026 此次是公司继 2012 年首次参与美国 FDA 现场检查以来，第五次通过 FDA 现场检查，表明公司高质量生产制造规范持续获得国际权威机构的认可。本次"零 缺陷通过"为 FDA 对药品生产质量体系合规性的最高认可，标志着公司质量管 理体系达到国际高标准。该质量体系为公司产品满足国际法规要求提供可靠支持， 有助于增强全球合作伙伴对公司产品合规性与质量的信心，为拓展国际市场创造 有利条件，进一步提升公司国际竞争力，对公司未来发展产生积极影响。 由于医药行业特点，原料药产品生产、销售受到行业政策、市场环境、供求 关系等因素影响，具有一定的不确定性。敬请广大投资者理性决策，注意投资风 险。 特此公告。 华熙生物科技股份有限公司董事会 2025 年 7 月 10 日 1 华熙生物科技股份有限公司 关于自愿披露公司通过美国 FDA 现场检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 华熙生物科技股份有限公司（以下简称"公司"）于 2025 年 3 月 ...